Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
This comprehensive resource covers product change evaluation, postmarket surveillance, audit/inspection compliance, and various other laws and regulations pertaining to maintaining a product on the market.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Regulatory News | 06 September 2016 | By Zachary Brennan
The US Food and Drug Administration (FDA) on Tuesday released a Form 483 for Valeant’s Bausch & Lomb sterile drug manufacturing facility in Tampa, FL, citing the site for microbiological contamination of drugs purporting to be sterile.
The eight-day inspection last February uncovered four observations detailing:
FDA’s Michael Tollon said in the report that he found “non-viable particles exceeding action limits on aseptic filling lines used in the manufacture of several eye drop solutions, including Latantoprost Ophthalmic Solution (0.005%), Opcon-A, Ketotifen Fumarate Ophthalmic Solution (0.025%) and Tobramycin Ophthalmic Solution, USP (0.3%).
Bausch & Lomb’s investigations into the nonconformities also were found to be incomplete and potential root causes were not always identified, with some excursions attributed to a bottle and bottle component “without scientific justification.” Valeant did not respond to a request for comment.
The release of the Form 483 for Bausch & Lomb comes more than three years since Valeant acquired the company for $8.7 billion in 2013, then laid off a couple thousand of its employees, and more recently, some are calling on Valeant to sell the company to pay off debt.
Those calls to sell Bausch came a month before the Senate Special Aging Committee revealed last May that Valeant jacked up the prices of a number of drugs by as much as 6,000%.
Tags: Valeant Pharmaceuticals, Bausch & Lomb, FDA Form 483